ECOG-ACRIN EA6174: STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Objective

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

https://clinicaltrials.gov/ct2/show/NCT03712605

Location: Essentia Health Cancer Centers

Research Study Categories

  • Adult Studies

Specialty

  • Skin Cancer
Contact
Cancer Clinical Trials at 844-681-7944
or cancertrials@essentiahelath.org

Like most websites, we use cookies and other technologies to keep our website reliable, secure, and to better understand how our site is used. By using our site, you agree to our use of these tools. Learn more.